Clinical Trial

A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 30, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1042 moves through the body of healthy adult participants.
Trial Details
NCT Number NCT07222709
Lead Sponsor AbbVie
Conditions Healthy Volunteer
Enrollment 48 participants
Start Date 2025-10-27
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2025-10-30